Investors with a lot of money to spend have taken a bearish stance on Gilead Sciences GILD.
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with GILD, it often means somebody knows something is about to happen.
So how do we know what these investors just did?
Today, Benzinga's options scanner spotted 15 uncommon options trades for Gilead Sciences.
This isn't normal.
The overall sentiment of these big-money traders is split between 20% bullish and 80%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $108,790, and 13 are calls, for a total amount of $1,178,713.
Projected Price Targets
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $100.0 to $110.0 for Gilead Sciences during the past quarter.
Volume & Open Interest Trends
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Gilead Sciences's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Gilead Sciences's substantial trades, within a strike price spectrum from $100.0 to $110.0 over the preceding 30 days.
Gilead Sciences 30-Day Option Volume & Interest Snapshot
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GILD | CALL | SWEEP | BEARISH | 04/17/25 | $7.6 | $7.35 | $7.5 | $105.00 | $162.0K | 1.0K | 433 |
| GILD | CALL | SWEEP | BEARISH | 04/17/25 | $7.55 | $7.5 | $7.5 | $105.00 | $150.0K | 1.0K | 217 |
| GILD | CALL | SWEEP | BEARISH | 04/17/25 | $7.15 | $7.0 | $7.0 | $105.00 | $145.7K | 1.0K | 812 |
| GILD | CALL | SWEEP | BULLISH | 04/17/25 | $7.1 | $6.95 | $6.98 | $105.00 | $145.0K | 1.0K | 1.0K |
| GILD | CALL | SWEEP | BULLISH | 04/17/25 | $5.75 | $5.6 | $5.75 | $107.00 | $115.0K | 104 | 701 |
About Gilead Sciences
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
In light of the recent options history for Gilead Sciences, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Present Market Standing of Gilead Sciences
- Currently trading with a volume of 2,915,168, the GILD's price is up by 1.67%, now at $111.09.
- RSI readings suggest the stock is currently may be approaching overbought.
- Anticipated earnings release is in 28 days.
Expert Opinions on Gilead Sciences
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $131.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access. * Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for Gilead Sciences, targeting a price of $130. * An analyst from Oppenheimer has decided to maintain their Outperform rating on Gilead Sciences, which currently sits at a price target of $132. * An analyst from B of A Securities has decided to maintain their Buy rating on Gilead Sciences, which currently sits at a price target of $126. * An analyst from Wells Fargo persists with their Overweight rating on Gilead Sciences, maintaining a target price of $140. * Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Gilead Sciences, targeting a price of $130.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Gilead Sciences, Benzinga Pro gives you real-time options trades alerts.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
